News Releases

Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting

Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business

Novel Oral Antibiotic SEYSARA™ (sarecycline) Now Available

Almirall LLC Launches New Name at Fall Clinical Dermatology Congress

Almirall acquires Allergan U.S. medical dermatology portfolio